Literature DB >> 17109845

Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells.

Han-Chieh Ko1, Yea-Hwey Wang, Kuo-Tong Liou, Chi-Ming Chen, Chih-Hsiang Chen, Wen-Yen Wang, Shiou Chang, Yu-Chang Hou, Kuo-Tung Chen, Chieh-Fu Chen, Yuh-Chiang Shen.   

Abstract

Evodia rutaecarpa is commonly used as an anti-inflammatory drug in traditional Chinese medicine. We previously identified four bioactive compounds (dehydroevodiamine (I), evodiamine (II), rutaecarpine (III), and synephrine (IV)) from the ethanol extract of E. rutaecarpa, but their effects and mechanism(s) of action remain unclear. To study the anti-inflammatory potential and the possible underlying mechanism(s), their effects on phorbol-12-myristate-13-acetate (PMA)- and N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced reactive oxygen species production in neutrophils was studied, as well as lipopolysaccharide (LPS)-induced nitric oxide (NO) production and inducible NO synthetase (iNOS) expression in microglial cells. The ethanol extract of E. rutaecarpa displayed potent antioxidative effects against both PMA- and fMLP-induced reactive oxygen species production in neutrophils (with IC50 values of around 2.7-3.3 microg/ml). Although less potent than the ethanol extract of E. rutaecarpa, compounds I-IV all concentration-dependently inhibited PMA- and fMLP-induced reactive oxygen species production, with compound IV consistently being the most potent agent among these active components. The antioxidative effects of the ethanol extract of E. rutaecarpa and these compounds were partially due to inhibition (10%-33%) of NADPH oxidase activity, a predominant reactive oxygen species-producing enzyme in neutrophils, and to a minor extent to their direct radical-scavenging properties. The ethanol extract of E. rutaecarpa also inhibited LPS-induced NO production (with an IC50 of around 0.8 microg/ml) and iNOS upregulation in microglial cells that was partially mimicked by compounds I, II, and III, but not compound IV. Our results suggest that the ethanol extract of E. rutaecarpa and its four bioactive components all exhibited anti-inflammatory activities which could be partially explained by their different potentials for inhibiting NADPH oxidase-dependent reactive oxygen species and/or iNOS-dependent NO production in activated inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109845     DOI: 10.1016/j.ejphar.2006.10.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  41 in total

1.  Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:  Shu-min Yuan; Kai Gao; Dong-mei Wang; Xiong-zhi Quan; Jiang-ning Liu; Chun-mei Ma; Chuan Qin; Lian-feng Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

Review 2.  Natural compounds from traditional medicinal herbs in the treatment of cerebral ischemia/reperfusion injury.

Authors:  Peng-fei WU; Zui ZHANG; Fang WANG; Jian-guo CHEN
Journal:  Acta Pharmacol Sin       Date:  2010-12       Impact factor: 6.150

3.  Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-κB by Inhibiting IκBα Phosphorylation.

Authors:  Xia Fan; Jun-Yu Zhu; Yu Sun; Li Luo; Jun Yan; Xue Yang; Jing Yu; Wan-Qi Tang; Wei Ma; Hua-Ping Liang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

4.  Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT.

Authors:  Yanni Xu; Qi Liu; Yang Xu; Chang Liu; Xiao Wang; Xiaobo He; Ningyu Zhu; Jikai Liu; Yexiang Wu; Yongzhen Li; Ni Li; Tingting Feng; Fangfang Lai; Murui Zhang; Bin Hong; Jian-Dong Jiang; Shuyi Si
Journal:  J Lipid Res       Date:  2014-06-07       Impact factor: 5.922

5.  Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.

Authors:  Luciano De Petrocellis; Aniello Schiano Moriello; Gabriele Fontana; Alessandro Sacchetti; Daniele Passarella; Giovanni Appendino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

6.  p-Synephrine suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-κB signaling pathway.

Authors:  Qianchao Wu; Ruisheng Li; Lanan Wassy Soromou; Na Chen; Xue Yuan; Guoquan Sun; Beibei Li; Haihua Feng
Journal:  Inflamm Res       Date:  2014-02-01       Impact factor: 4.575

7.  Evodiamine ameliorates liver fibrosis in rats via TGF-β1/Smad signaling pathway.

Authors:  Dongmei Yang; Li Li; Shanjun Qian; Lixin Liu
Journal:  J Nat Med       Date:  2017-09-21       Impact factor: 2.343

8.  Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.

Authors:  Le Shi; Fan Yang; Fei Luo; Yi Liu; Feng Zhang; Meijuan Zou; Qizhan Liu
Journal:  Tumour Biol       Date:  2016-07-23

9.  Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.

Authors:  Y-H Wang; Y-C Shen; J-F Liao; C-H Lee; C-H Li; C-Y Chou; K-T Liou; Y-C Chou
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

10.  Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma.

Authors:  V R M Lombardi; E Martínez; R Chacón; I Etcheverría; R Cacabelos
Journal:  J Biomed Biotechnol       Date:  2009-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.